These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25367188)

  • 1. Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention.
    Ceppi F; Cazzaniga G; Colombini A; Biondi A; Conter V
    Expert Rev Hematol; 2015 Feb; 8(1):57-70. PubMed ID: 25367188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
    Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
    Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low expressions of ARS2 and CASP8AP2 predict relapse and poor prognosis in pediatric acute lymphoblastic leukemia patients treated on China CCLG-ALL 2008 protocol.
    Cui L; Gao C; Zhang RD; Jiao Y; Li WJ; Zhao XX; Liu SG; Yue ZX; Zheng HY; Deng GR; Wu MY; Li ZG; Jia HT
    Leuk Res; 2015 Feb; 39(2):115-23. PubMed ID: 25530566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
    Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
    N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. E2F3a gene expression has prognostic significance in childhood acute lymphoblastic leukemia.
    Wang KL; Mei YY; Cui L; Zhao XX; Li WJ; Gao C; Liu SG; Jiao Y; Liu FF; Wu MY; Ding W; Li ZG
    Eur J Haematol; 2014 Oct; 93(4):281-9. PubMed ID: 24758291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
    Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
    J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of late cell cycle genes and an increased proliferative capacity characterize very early relapse of childhood acute lymphoblastic leukemia.
    Kirschner-Schwabe R; Lottaz C; Tödling J; Rhein P; Karawajew L; Eckert C; von Stackelberg A; Ungethüm U; Kostka D; Kulozik AE; Ludwig WD; Henze G; Spang R; Hagemeier C; Seeger K
    Clin Cancer Res; 2006 Aug; 12(15):4553-61. PubMed ID: 16899601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
    Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
    Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
    Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
    Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Childhood acute lymphoblastic leukemia: update on prognostic factors.
    Vrooman LM; Silverman LB
    Curr Opin Pediatr; 2009 Feb; 21(1):1-8. PubMed ID: 19242236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.
    Ballerini P; Landman-Parker J; Cayuela JM; Asnafi V; Labopin M; Gandemer V; Perel Y; Michel G; Leblanc T; Schmitt C; Fasola S; Hagemejier A; Sigaux F; Auclerc MF; Douay L; Leverger G; Baruchel A
    Haematologica; 2008 Nov; 93(11):1658-65. PubMed ID: 18835836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of relapse in paediatric pre-B acute lymphoblastic leukaemia using a three-gene risk index.
    Hoffmann K; Firth MJ; Beesley AH; Freitas JR; Ford J; Senanayake S; de Klerk NH; Baker DL; Kees UR
    Br J Haematol; 2008 Mar; 140(6):656-64. PubMed ID: 18302714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia.
    Laughton SJ; Ashton LJ; Kwan E; Norris MD; Haber M; Marshall GM
    J Clin Oncol; 2005 Apr; 23(10):2264-71. PubMed ID: 15800317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Association of miRNAs expression profiles with prognosis and relapse in childhood acute lymphoblastic leukemia].
    Xu L; Liang YN; Luo XQ; Liu XD; Guo HX
    Zhonghua Xue Ye Xue Za Zhi; 2011 Mar; 32(3):178-81. PubMed ID: 21535956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
    Balduzzi A; Di Maio L; Silvestri D; Songia S; Bonanomi S; Rovelli A; Conter V; Biondi A; Cazzaniga G; Valsecchi MG
    Br J Haematol; 2014 Feb; 164(3):396-408. PubMed ID: 24422724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential of gene expression profiling in the management of childhood acute lymphoblastic leukemia.
    Bhojwani D; Moskowitz N; Raetz EA; Carroll WL
    Paediatr Drugs; 2007; 9(3):149-56. PubMed ID: 17523695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
    Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
    Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of glutathione S-transferase gene deletion on early relapse in childhood B-precursor acute lymphoblastic leukemia.
    Takanashi M; Morimoto A; Yagi T; Kuriyama K; Kano G; Imamura T; Hibi S; Todo S; Imashuku S
    Haematologica; 2003 Nov; 88(11):1238-44. PubMed ID: 14607752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.